Built Like A Tech Company: Why CROs Need A New Operating System

By Ander Tallett, COO, Dash Bio

Bioanalysis is undergoing a pivotal transformation, much like the shift from human “computers” to electronic machines in the mid-20th century. Traditional clinical bioanalysis, reliant on manual workflows and siloed systems, can no longer keep up with today’s complex drug development landscape involving biologics, gene therapies, and massive data volumes. Many CROs still operate using disconnected instruments, separate LIMS, and manual sample tracking, which causes delays and inefficiencies that impede scalability and predictability.

A tech-native model, inspired by modern software companies, applies automation, continuous quality monitoring, and integrated, version-controlled processes. This approach eliminates repetitive manual tasks, reduces errors, and aligns business models around fixed pricing and outcomes instead of billable hours. Regulatory frameworks like ICH M10 mandate continuous verification and traceability, which legacy systems struggle to meet but tech-driven platforms naturally support.

Dash Bio has built this type of infrastructure, automating sample handling, integrating study management, and providing real-time data monitoring with transparent tracking. Scientists can focus on interpreting results while technology drives speed, compliance, and quality. For drug development, platform-based CROs are essential to meet growing complexity and accelerate therapies to patients.